A low-toxic site-directed mutant of Clostridium perfringens ε-toxin as a potential candidate vaccine against enterotoxemia

Human Vaccines and Immunotherapeutics

Volumn 9, Issue 11, 2013, Pages 2386-2392

  Li, Qing ^a,b   Xin, Wenwen ^b   Gao, Shan ^b   Kang, Lin ^b   Wang, Jinglin ^b  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

Author keywords

Clostridium perfringens; Cytotoxicity; Enterotoxemia; Site directed mutagenesis; Toxin mutant; Vaccine; toxin

Indexed keywords

CLOSTRIDIUM PERFRINGENS EPSILON TOXIN; CLOSTRIDIUM TOXIN; IMMUNOGLOBULIN G ANTIBODY; UNCLASSIFIED DRUG; BACTERIAL ANTIGEN; BACTERIAL TOXIN; BACTERIAL VACCINE; CLOSTRIDIUM PERFRINGENS EPSILON-TOXIN; MUTANT PROTEIN; RECOMBINANT VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DETOXIFICATION; DRUG CYTOTOXICITY; ENDOTOXEMIA; ENTEROTOXEMIA; ESCHERICHIA COLI; FEMALE; IMMUNOGENICITY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; SITE DIRECTED MUTAGENESIS; SURVIVAL RATE; ANIMAL; BAGG ALBINO MOUSE; CLOSTRIDIUM PERFRINGENS; DISEASE MODEL; DOG; GENE EXPRESSION; GENETICS; HUMAN; IMMUNOLOGY; MDCK CELL LINE; SURVIVAL; TOXEMIA; TOXICITY;

ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL TOXINS; BACTERIAL VACCINES; CLOSTRIDIUM PERFRINGENS; DISEASE MODELS, ANIMAL; DOGS; ESCHERICHIA COLI; FEMALE; GENE EXPRESSION; HUMANS; MADIN DARBY CANINE KIDNEY CELLS; MICE, INBRED BALB C; MUTAGENESIS, SITE-DIRECTED; MUTANT PROTEINS; SURVIVAL ANALYSIS; TOXEMIA; VACCINES, SYNTHETIC;

EID: 84887429844     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.25649     Document Type: Article

References (24)

1. Popoff MR. Epsilon toxin: a fascinating pore-forming toxin. FEBS J 2011; 278: 4602-15; PMID: 21535407; ht t p://d x.d o i.or g/10.1111/j.174 2 - 4 658. 2 011. 0 8145. x
2. Minami J, Katayama S, Matsushita O, Matsushita C, Okabe A. Lambda-toxin of Clostridium perfringens activates the precursor of epsilon-toxin by releasing its N- and C-terminal peptides. Microbiol Immunol 1997; 41: 527-35; PMID: 9272698 (Pubitemid 27318089)
3. Rood JI. Virulence genes of Clostridium perfringens. Annu Rev Microbiol 1998; 52: 333-60; PMID: 9891801; ht t p://d x.do i.or g/10.114 6/a n nu r e v. micro.52.1.333 (Pubitemid 28481195)
4. Shortt SJ, Titball RW, Lindsay CD. An assessment of the in vitro toxicology of Clostridium perfringens type D epsilon-toxin in human and animal cells. Hum E x p To x i c o l 2000; 19: 108-16; PMID: 10773840; http://dx.doi.org/10.1191/096032700678815710 (Pubitemid 30189872)
5. Fernandez Miyakawa ME, Zabal O, Silberstein C. Clostridium perfringens epsilon toxin is cytotoxic for human renal tubular epithelial cells. Hum Exp To x i c o l 2 011; 30: 275-82; PMID: 20488848; http://dx.doi.org/10.1177/ 0960327110371700
6. Ivie SE, Fennessey CM, Sheng J, Rubin DH, McClain MS. Gene-trap mutagenesis identifes mammalian genes contributing to intoxication by Clostridium perfringens e-toxin. PLoS One 2011; 6:e17787; PMID: 21412435; http://dx.doi.org/10.1371/journal. pone.0 017787
7. Titball RW. Clostridium perfringens vaccines. Vaccine 2009; 27(Suppl 4):D44-7; PMID: 19837285; http://dx.doi.org/10.1016/j.vaccine.2009.07.047
8. Uzal FA, Wong JP, Kelly WR, Priest J. Antibody response in goats vaccinated with liposome-adjuvanted Clostridium perfringens type D epsilon toxoid. Vet Res Commun 1999; 23: 143-50; PMID: 10401718; http://dx.doi.org/10. 1023/A: 1006206216220 (Pubitemid 29266190)
9. Uzal FA, Bodero DA, Kelly WR, Nielsen K. Variability of serum antibody responses of goat kids to a commercial Clostridium perfringens epsilon toxoid vaccine. Vet Rec 1998; 143: 472-4; PMID: 9829304; http://dx.doi.org/10.1136/vr. 143.17.472 (Pubitemid 28493038)
10. Oyston PC, Payne DW, Havard HL, Williamson ED, Titball RW. Production of a non-toxic site-directed mutant of Clostridium perfringens epsilon-toxin which induces protective immunity in mice. Microbiology 1998; 144: 333-41; PMID: 9493371; http://dx.doi.org/10.1099/00221287-144-2-333 (Pubitemid 28067738)
11. Lobato FC, Lima CG, Assis RA, Pires PS, Silva RO, Salvarani FM, et al. Potency against enterotoxemia of a recombinant Clostridium perfringens type D epsilon toxoid in ruminants. Vacci ne 2010; 28: 6125-7; PMID: 20670910; http://dx.doi.org/10.1016/j. vaccine.2010.07.046
12. Mathur DD, Deshmukh S, Kaushik H, Garg LC. Functional and structural characterization of soluble recombinant epsilon toxin of Clostridium perfringens D, causative agent of enterotoxaemia. Appl Microbiol Biotechnol 2010; 88: 877-84; PMID: 20676627; http://dx.doi.org/10.1007/s00253-010-2785-y
13. Souza AM, Reis JK, Assis RA, Horta CC, Siqueira FF, Facchin S, et al. Molecular cloning and expression of epsilon toxin from Clostridium perfringens type D and tests of animal immunization. Genet Mol Res 2010; 9: 266-76; PMID: 2 019 85 82; http://dx.doi.org/10.4238/vol9-1gmr711
14. Cole AR, Gibert M, Popoff M, Moss DS, Titball RW, Basak AK. Clostridium perfringens epsilon-toxin shows structural similarity to the pore-forming toxin aerolysin. Nat Struct Mol Biol 2004; 11: 797-8; PMID: 15258571; http://dx.doi.org/10.1038/nsmb804 (Pubitemid 39014507)
15. Ivie SE, McClain MS. Identifcation of amino acids important for binding of Clostridium perfringens epsilon toxin to host cells and to HAVCR1. Biochemistry 2012; 51: 7588-95; PMID: 22938730; http://dx.doi.org/10.1021/ bi300690a
16. Knapp O, Maier E, Benz R, Geny B, Popoff MR. Identifcation of the channel-forming domain of Clostridium perfringens Epsilon-toxin (ETX). Biochim Biophys Acta 2009; 1788: 2584-93; PMID: 19835840; http://dx.doi.org/10.1016/j. bbamem.2009.09.020
17. Pelish TM, McClain MS. Dominant-negative inhibitors of the Clostridium perfringens epsilon-toxin. J Biol Chem 2009; 284: 29446-53; PMID: 19720828; http://dx.doi.org/10.1074/jbc. M109.021782
18. Worthing ton RW, Mülders MS. Physical changes in the epsilon prototoxin molecule of Clostridium perfringens during enzymatic activation. Infect Immun 1977; 18: 549-51; PMID: 200566 (Pubitemid 8231936)
19. Bhown AS, Habeerb AF. Structural studies on epsilon-prototoxin of Clostridium perfringens type D. Localization of the site of tryptic scission necessary for activation to epsilon-toxin. Biochem Biophys Res Commun 197 7; 78: 889-96; PMID: 199192; http://dx.doi.org/10.1016/0006-291X(77)90506-X (Pubitemid 8209820)
20. Zhao Y, Kang L, Gao S, Zhou Y, Su L, Xin W, et al. Expression and purifcation of functional Clostridium perfringens alpha and epsilon toxins in Escherichia coli. Protein Expr Purif 2011; 77: 207-13; PMID: 21300155; http://dx.doi.org/10.1016/j. pep.2011.02.001
21. Payne DW, Williamson ED, Havard H, Modi N, Brown J. Evaluation of a new cytotoxicity assay for Clostridium perfringens type D epsilon toxin. FEMS Microbiol Lett 1994; 116: 161-7; PMID: 7512061; http://dx.doi.org/10.1111/j. 1574-6968.1994. tb06695.x (Pubitemid 124011993)
22. Han YH, Gao S, Xin W W, Kang L, Wang JL. A recombinant mutant abrin A chain expressed in Escherichia coli can be used as an effective vaccine candidate. Hum Vac cin 2011; 7: 838-44; PMID: 21817853; http://dx.doi.org/10. 4161/h v.7. 8.16258
23. Braman J, Papworth C, Greener A. Site-directed mutagenesis using double-stranded plasmid DNA templates. Methods Mol Biol 1996; 57: 31-44; PMID: 8849992
24. McClain MSCT, Cover TL. Functional analysis of neutralizing antibodies against Clostridium perfringens epsilon-toxin. Infect Immun 2007; 75: 1785-93; PMID: 17261609; http://dx.doi.org/10.1128/IAI.01643-06 (Pubitemid 46559446)